A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS).

ABSTRACT:

Objective

This study aimed to analyze the FAERS database to identify adverse event associated with sunitinib to offer valuable insights for the judicious utilization of medication in clinical settings.

Methods

Various disproportionality analysis techniques, such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPN), and multi-gamma Poisson shrinkage (MGPS), were employed to analyze adverse drug reaction (ADR) reports pertaining to sunitinib in the FAERS database from its market introduction up to the first quarter of 2023. Subsequently, a secondary screening process was conducted to identify reliable positive signals.

Results

The analysis of sunitinib adverse event signals at the system-organ class

SUBMITTER: Zou W 

PROVIDER: S-EPMC11409130 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature